David A. Siegel Intellia Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,998,317 shares of NTLA stock, worth $20.7 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,998,317
Previous 1,027,617
94.46%
Holding current value
$20.7 Million
Previous $21.1 Million
10.34%
% of portfolio
0.06%
Previous 0.05%
Shares
25 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
96.1MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$130 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$105 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$99.3 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$53.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$39.5 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $787M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...